Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Belantamab mafodotin induces immunogenic cell death within 24-hrs of administration in NDMM

Ioannis Ntanasis-Stathopoulos • 29 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Belantamab mafodotin Dexamethasone Lenalidomide

Ioannis Ntanasis-Stathopoulos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the results of a study investigating the use of belantamab mafodotin in combination with lenalidomide and dexamethasone (Rd) in the treatment of patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ioannis Ntanasis-Stathopoulos

1:42
The use of CTCs as a prognostic tool in NDMM
Ioannis Ntanasis-Stathopoulos • 29 Sep 2023
2:09
CTCs as a prognostic indicator in patients with newly diagnosed multiple myeloma
Ioannis Ntanasis-Stathopoulos • 29 Sep 2023
4:32
Real-world efficacy and safety of belantamab mafodotin in patients with triple class-exposed myeloma
Ioannis Ntanasis-Stathopoulos • 12 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals